Heart failure therapy with either angiotensin-converting enzyme inhibitors (ACE-I), angiotensin-1 receptor antagonists (AT), or an AT/neprilysin inhibitor was implemented in 98% of patients with ICM, in all patients with DCM, and in 79% of patients with group 3 indications for WCD. This evidence concerns the gene ACE and familial dilated cardiomyopathy.